Non-Cystic Fibrosis Bronchiectasis

Rare Diseases
8
Pipeline Programs
7
Companies
9
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
5
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Insmed
InsmedBRIDGEWATER, NJ
3 programs
1
1
Brensocatib 10 mgPhase 31 trial
Brensocatib 10 mgPhase 21 trial
BrensocatibN/A1 trial
Active Trials
NCT05344508Approved For Marketing
NCT03218917Completed256Est. Dec 2019
NCT04594369Completed1,767Est. Oct 2024
Armata Pharmaceuticals
Armata PharmaceuticalsLOS ANGELES, CA
1 program
1
AP-PA02Phase 21 trial
Active Trials
NCT05616221CompletedEst. Aug 2024
Renovion
RenovionNC - Chapel Hill
1 program
1
ARINA-1Phase 21 trial
Active Trials
NCT05495243CompletedEst. Feb 2024
CSL Behring
CSL BehringIL - Bradley
1 program
1
CSL787Phase 21 trial
Active Trials
NCT07048262Recruiting450Est. Mar 2028
Verona Pharma
Verona PharmaUK - London
1 program
1
Nebulized Ensifentrine Suspension; 3 mgPhase 21 trial
Active Trials
NCT06559150Recruiting180Est. Sep 2026
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
BI 1323495Phase 11 trial
Active Trials
NCT04656275Terminated7Est. Jan 2022
Genentech
GenentechCA - Oceanside
1 program
1
GDC-6988Phase 11 trial
Active Trials
NCT06603246Recruiting128Est. Jul 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
InsmedBrensocatib 10 mg
CSL BehringCSL787
Verona PharmaNebulized Ensifentrine Suspension; 3 mg
Armata PharmaceuticalsAP-PA02
RenovionARINA-1
InsmedBrensocatib 10 mg
GenentechGDC-6988
Boehringer IngelheimBI 1323495

Clinical Trials (9)

Total enrollment: 2,788 patients across 9 trials

NCT04594369InsmedBrensocatib 10 mg

A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis

Start: Dec 2020Est. completion: Oct 20241,767 patients
Phase 3Completed
NCT07048262CSL BehringCSL787

Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)

Start: Sep 2025Est. completion: Mar 2028450 patients
Phase 2Recruiting
NCT06559150Verona PharmaNebulized Ensifentrine Suspension; 3 mg

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

Start: Sep 2024Est. completion: Sep 2026180 patients
Phase 2Recruiting
NCT05616221Armata PharmaceuticalsAP-PA02

Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Start: Jan 2023Est. completion: Aug 2024
Phase 2Completed
NCT05495243RenovionARINA-1

Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough

Start: Oct 2022Est. completion: Feb 2024
Phase 2Completed
NCT03218917InsmedBrensocatib 10 mg

Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis

Start: Oct 2017Est. completion: Dec 2019256 patients
Phase 2Completed
NCT06603246GenentechGDC-6988

A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease

Start: Nov 2024Est. completion: Jul 2027128 patients
Phase 1Recruiting
NCT04656275Boehringer IngelheimBI 1323495

A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation

Start: Mar 2021Est. completion: Jan 20227 patients
Phase 1Terminated
NCT05344508InsmedBrensocatib

An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis

N/AApproved For Marketing

Related Jobs in Rare Diseases

Manager, Gene Therapy Operations (GTO)

Genetix Biotherapeutics
8h ago
From $130K/yr

Manager, Gene Therapy Operations (GTO)

Genetix Biotherapeutics
Somerville, Massachusetts, United States
8h ago

Medical Engagement Manager – Diamyd Medical

Bonesupport
Stockholm, Sweden
Yesterday

Exec. Director, Global Patient Engagement

BioCryst Pharmaceuticals
US_North Carolina_Headquarters
Yesterday

Sr. Director, Regulatory CMC

Genetix Biotherapeutics
Somerville, MA
4d ago
From $270K/yr

Associate Director, Quality Systems

Genetix Biotherapeutics
Somerville, Massachusetts
4d ago
From $165K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 2,788 patients
7 companies competing in this space

Related Indications

Cystic Fibrosis(244)Hemophilia A(139)Sickle Cell Disease(64)Fabry Disease(55)Duchenne Muscular Dystrophy(53)Hemophilia B(47)Spinal Muscular Atrophy(34)Phenylketonuria(32)Gaucher Disease(29)Severe Hemophilia A(26)